Sympathetic Control of Ventricular Relaxation

Sympathetic Control of Ventricular Relaxation is the process by which sympathetic stimulation accelerates myocardial relaxation between contractions, a property known as positive lusitropy, ensuring that diastolic filling remains efficient even as heart rate rises and the time available for filling shortens. This regulation is functionally inseparable from sympathetic control of contractility, since the same signaling cascade that strengthens contraction also speeds relaxation, allowing the heart to beat faster and harder without sacrificing adequate diastolic filling.

The Problem Sympathetic Lusitropy Solves

Diastolic Time Shrinks Disproportionately with Heart Rate

As heart rate increases, the duration of diastole shortens far more than the duration of systole, since systolic ejection time is relatively fixed while the entire reduction in cycle length is absorbed largely by diastole. Without a compensatory acceleration of relaxation, faster heart rates would risk incomplete ventricular relaxation before the next contraction, reducing effective filling and stroke volume despite the heart beating more often.

Where total cycle length $T$ is divided between relatively fixed systolic time and increasingly compressed diastolic time as heart rate $\mathrm{HR}$ rises, creating the physiological need for a mechanism that accelerates the relaxation phase specifically.

Lusitropy as a Rate-Matched Adaptation

Sympathetically driven lusitropy shortens the time constant of isovolumic relaxation and speeds the decline of ventricular pressure and calcium concentration after each contraction, effectively compressing the relaxation process to fit within the shortened diastolic window imposed by tachycardia.

Cellular Mechanism

Phospholamban Phosphorylation and Calcium Reuptake

Protein kinase A, activated downstream of beta-1 adrenergic receptor stimulation, phosphorylates phospholamban, an inhibitory regulator of the sarcoplasmic reticulum calcium ATPase (SERCA2a). Phosphorylated phospholamban releases its inhibition of SERCA2a, accelerating the rate at which cytosolic calcium is pumped back into the sarcoplasmic reticulum after each contraction, directly speeding the decline of intracellular calcium that permits myofilament relaxation.

Troponin I Phosphorylation

Protein kinase A also phosphorylates troponin I, reducing the calcium sensitivity of the contractile apparatus and accelerating the dissociation of calcium from troponin C, which speeds cross-bridge detachment and myofilament relaxation independent of, and in addition to, the effect on sarcoplasmic reticulum calcium reuptake.

Functional Consequences

Preservation of Stroke Volume at High Heart Rates

By accelerating relaxation and lowering end-systolic and diastolic pressures more rapidly, sympathetic lusitropy allows the ventricle to fill adequately even during the abbreviated diastole of tachycardia, supporting the maintenance or increase of stroke volume during exercise despite substantially elevated heart rate.

Contribution to Increased Cardiac Reserve

Enhanced lusitropy, together with the concurrently increased contractility and heart rate discussed under Sympathetic Control of Myocardial Contractility and Autonomic Control of Sinoatrial Node Rate, forms one of three coordinated sympathetic adaptations that together allow cardiac output to increase several-fold during maximal exertion without any single parameter becoming a limiting bottleneck.

Relationship to Diastolic Pressure-Volume Dynamics

Effect on the Isovolumic Relaxation Period

Sympathetic stimulation shortens the isovolumic relaxation period, the interval between aortic valve closure and mitral valve opening during which ventricular pressure falls without a change in volume, allowing earlier onset of diastolic filling relative to the cardiac cycle.

Interaction with Passive Ventricular Properties

While sympathetic signaling actively accelerates the early, energy-dependent phase of relaxation, the later phase of diastolic filling remains governed by the passive elastic and viscoelastic properties of the ventricular wall, which are not directly modified by acute sympathetic stimulation, meaning lusitropic support has diminishing benefit in conditions where passive stiffness, rather than active relaxation, is the limiting factor.

Clinical Relevance

Diastolic Dysfunction and Impaired Lusitropic Reserve

Conditions such as left ventricular hypertrophy, myocardial ischemia, and aging are associated with impaired active relaxation and reduced lusitropic responsiveness to sympathetic stimulation, contributing to exercise intolerance and, in more severe cases, heart failure with preserved ejection fraction, where inadequate diastolic filling reserve limits cardiac output despite normal systolic function.

Pharmacological Relevance

Beta-agonists enhance lusitropy alongside inotropy, useful in acute decompensated states requiring both stronger and faster relaxation-compatible contractions, while beta-blockers, despite reducing acute lusitropic reserve, are used chronically in heart failure management for their favorable long-term effects on myocardial remodeling and receptor sensitivity.